Covaxin has been indigenously developed in collaboration with ICMR.
An expert panel from India’s central drug authority recommended on January 2 to grant permission for the emergency restricted use of the locally developed COVID-19 vaccine Covaxin with certain conditions, a day after giving similar instructions for the COVID vaccine. -19 from Oxford, sources said.
Coronavirus | ‘Phase III trials of covaxin approaching 20,000 volunteers’
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR).
The Central Medicines Control Organization (CDSCO) Subject Matter Expert Committee (SEC) on COVID-19 on January 2 again deliberated on the Hyderabad-based pharmaceutical company emergency use authorization (USA) request after it presented data, facts and analysis after the Jan. 1 review meeting, a source said.
Bharat Biotech submitted an application to the Controller General of Drugs of India (DCGI) requesting an emergency use authorization for its Covaxin on December 7.
On January 1, the SEC recommended granting permission for the restricted emergency use of the Oxford-AstraZeneca Covishield vaccine, manufactured by the Serum Institute of India.
.
